加载中
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
前收盘价
US$17.86
+US$0.23 · +1.30%
盘前
US$17.71
−US$0.15 · -0.84%
10月13日 5:14 ET
盘中时间采用ET。市场数据可能有所延迟。
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
日内区间
当前US$17.86
52周区间
当前US$17.86
盘中时间采用ET。市场数据可能有所延迟。
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
日内区间
当前US$17.86
52周区间
当前US$17.86
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 1亿 USD | 6512.4万 USD | 1199.5万 USD | 17.9万 USD |
| 销货成本 | 4471.4万 USD | 2923.6万 USD | 568.7万 USD | — |
| 毛利 | 5553.7万 USD | 3588.8万 USD | 630.8万 USD | 17.9万 USD |
| 研究与开发 | 3478.9万 USD | 2618.4万 USD | 1794.3万 USD | 3142.8万 USD |
| 销售、一般及管理费用 | 9242.9万 USD | 5495.5万 USD | 2421.5万 USD | 3349.5万 USD |
| 营业费用 | 1.27亿 USD | 8113.9万 USD | 4215.8万 USD | 6602.3万 USD |
| 利息收入 | 1093.2万 USD | 390.9万 USD | 177.7万 USD | 19.6万 USD |
| 利息支出 | — | — | — | 1.4万 USD |
| 折旧和摊销 | 287.5万 USD | 228.3万 USD | 209.1万 USD | 208.7万 USD |
| 营业利润 | −7168.1万 USD | −4525.1万 USD | −3585万 USD | −6584.4万 USD |
| 净利润 | −7320万 USD | −5475.6万 USD | −4409.9万 USD | −6475.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$24.75
上涨空间 38.58%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2538.65万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1876.09万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF937.84万0.01%954亿 USD0.05%US$233.52-0.63%
T. Rowe Price Small-Mid Cap ETFTMSL533.79万0.17%30.87亿 USD0.55%US$40.99-0.46%
Vanguard Russell 2000 ETFVTWO466.66万0.03%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA428.22万0.02%218.24亿 USD0.03%US$32.66-0.40%
iShares U.S. Medical Devices ETFIHI392.73万0.11%35.74亿 USD0.37%US$52.79+2.03%
State Street SPDR S&P Health Care Equipment ETFXHE283.56万1.63%1.74亿 USD0.35%US$90.87+1.59%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFT. Rowe Price Small-Mid Cap ETFTMSLVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIState Street SPDR S&P Health Care Equipment ETFXHEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
